Clinical Trials Logo

Clinical Trial Summary

This project aims to standardize the management of "Pharmaceutical care with the two-way text messages and incentive for mobile usage during the treatment for tuberculosis patients, to improve the outcomes and compliance, reduce the risk of transmission and to evaluate the patient perspective in terms of their quality of life, shared decision making and satisfaction with services provided.


Clinical Trial Description

Tuberculosis (TB) remains a top ten leading cause of death globally despite it being a largely curable disease. New effective treatment supervision strategies are needed particularly in low-resource high TB burden settings and a potential solution is in the hands of nearly every patient - a mobile phone. Modern modular design mobile phone software applications ("apps") hold great promise to address this unmet need. Current technologies allow for rapid design modification based on end-user needs, implementation of native operating system (e.g., Android) versions for users with inconsistent internet access, and the integration of the patients' experiences with electronic health records using industry standards. Apps can perform multiple functions (e.g., automated reminders, symptom tracking, secure messaging, and multi-media education). Another strategy is pharmaceutical care which is utilized to enhance TB treatment compliance along with usage of mobile technologies, where clinical pharmacists provide patient education to improve the patient's knowledge on the disease and medication use and address the patient's drug-related problems. The use of a pharmaceutical care model to improve treatment outcomes and enhance adherence is on the rise in healthcare organizations. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment. Patients will make prior arrangements with a study pharmacist to determine a convenient meeting place. These meetings will continue until treatment completion. To our knowledge, worldwide there has only been no randomized controlled trial (RCT) which has described the use of both pharmaceutical care model and two-way Short Message Service (SMS) communication with financial incentives (mobile money transfer cover healthcare costs related to SMS charges) to improve treatment outcomes. To find out both the pharmaceutical care model and two-way SMS communication with financial incentives would be helpful for TB patients in Pakistan. Therefore investigator aimed a study, to find out the effectiveness of trial gauged with the impact of the suggested model on the improved adherence, treatment completion, health-related quality of life and satisfaction with TB care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04645836
Study type Interventional
Source Health Science Center of Xi'an Jiaotong University
Contact
Status Completed
Phase N/A
Start date September 1, 2020
Completion date December 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT00480454 - Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines Phase 1
Active, not recruiting NCT03208725 - Childhood Acute Illness and Nutrition Network
Completed NCT00480688 - A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers Phase 1
Terminated NCT01055145 - Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients Phase 3
Completed NCT00480714 - A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers N/A
Active, not recruiting NCT04298905 - Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA N/A
Completed NCT00480558 - A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both Phase 1
Withdrawn NCT00424684 - Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation N/A
Recruiting NCT04673227 - Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
Completed NCT00654316 - Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine Phase 1
Active, not recruiting NCT05405296 - Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2)